Cargando…
Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant
BACKGROUND: Bovine viral diarrhea virus (BVDV) is one of the main causes of infectious diseases in cattle and causes large financial losses to the cattle industry worldwide. In this study, Lactobacillus casei strain W56 (Lc W56) was used as antigen deliver carrier to construct a recombinant Lactobac...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527787/ https://www.ncbi.nlm.nih.gov/pubmed/33004035 http://dx.doi.org/10.1186/s12934-020-01449-3 |
_version_ | 1783589131739201536 |
---|---|
author | Jia, Shuo Huang, Xinning Li, Hua Zheng, Dianzhong Wang, Li Qiao, Xinyuan Jiang, Yanping Cui, Wen Tang, Lijie Li, Yijing Xu, Yigang |
author_facet | Jia, Shuo Huang, Xinning Li, Hua Zheng, Dianzhong Wang, Li Qiao, Xinyuan Jiang, Yanping Cui, Wen Tang, Lijie Li, Yijing Xu, Yigang |
author_sort | Jia, Shuo |
collection | PubMed |
description | BACKGROUND: Bovine viral diarrhea virus (BVDV) is one of the main causes of infectious diseases in cattle and causes large financial losses to the cattle industry worldwide. In this study, Lactobacillus casei strain W56 (Lc W56) was used as antigen deliver carrier to construct a recombinant Lactobacillus vaccine pPG-E2-ctxB/Lc W56 constitutively expressing BVDV E2 protein fused with cholera toxin B subunit (ctxB) as an adjuvant, and its immunogenicity against BVDV infection in mice model by oral route was explored. RESULTS: Our results suggested that pPG-E2-ctxB/Lc W56 can effectively activate dendritic cells (DCs) in the Peyer’s patches, up-regulate the expression of Bcl-6, and promote T-follicular helper (Tfh) cells differentiation, as well as enhance B lymphocyte proliferation and promote them differentiate into specific IgA-secreting plasma cells, secreting anti-E2 mucosal sIgA antibody with BVDV-neutralizing activity. Moreover, significant levels (p < 0.01) of BVDV-neutralizing antigen-specific serum antibodies were induced in the pPG-E2-ctxB/LC W56 group post-vaccination. The recombinant Lactobacillus vaccine can induce cellular immune responses, and significant levels (p < 0.01) of Th1-associated cytokines (IL-2, IL-12, and IFN-γ), Th2-associated cytokines (IL-4, IL-10) and Th17-associated cytokine (IL-17) were determined in the serum of vaccinated mice. Significantly, the recombinant Lactobacillus vaccine provides immune protection against BVDV infection, which can be cleared effectively by the vaccine post-challenge in orally vaccinated animals. CONCLUSIONS: The genetically engineered Lactobacillus vaccine constructed in this study is immunogenic in mice and can induce mucosal, humoral, and cellular immune responses, providing effective anti-BVDV immune protection. It thus represents a promising strategy for vaccine development against BVDV. |
format | Online Article Text |
id | pubmed-7527787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75277872020-10-01 Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant Jia, Shuo Huang, Xinning Li, Hua Zheng, Dianzhong Wang, Li Qiao, Xinyuan Jiang, Yanping Cui, Wen Tang, Lijie Li, Yijing Xu, Yigang Microb Cell Fact Research BACKGROUND: Bovine viral diarrhea virus (BVDV) is one of the main causes of infectious diseases in cattle and causes large financial losses to the cattle industry worldwide. In this study, Lactobacillus casei strain W56 (Lc W56) was used as antigen deliver carrier to construct a recombinant Lactobacillus vaccine pPG-E2-ctxB/Lc W56 constitutively expressing BVDV E2 protein fused with cholera toxin B subunit (ctxB) as an adjuvant, and its immunogenicity against BVDV infection in mice model by oral route was explored. RESULTS: Our results suggested that pPG-E2-ctxB/Lc W56 can effectively activate dendritic cells (DCs) in the Peyer’s patches, up-regulate the expression of Bcl-6, and promote T-follicular helper (Tfh) cells differentiation, as well as enhance B lymphocyte proliferation and promote them differentiate into specific IgA-secreting plasma cells, secreting anti-E2 mucosal sIgA antibody with BVDV-neutralizing activity. Moreover, significant levels (p < 0.01) of BVDV-neutralizing antigen-specific serum antibodies were induced in the pPG-E2-ctxB/LC W56 group post-vaccination. The recombinant Lactobacillus vaccine can induce cellular immune responses, and significant levels (p < 0.01) of Th1-associated cytokines (IL-2, IL-12, and IFN-γ), Th2-associated cytokines (IL-4, IL-10) and Th17-associated cytokine (IL-17) were determined in the serum of vaccinated mice. Significantly, the recombinant Lactobacillus vaccine provides immune protection against BVDV infection, which can be cleared effectively by the vaccine post-challenge in orally vaccinated animals. CONCLUSIONS: The genetically engineered Lactobacillus vaccine constructed in this study is immunogenic in mice and can induce mucosal, humoral, and cellular immune responses, providing effective anti-BVDV immune protection. It thus represents a promising strategy for vaccine development against BVDV. BioMed Central 2020-10-01 /pmc/articles/PMC7527787/ /pubmed/33004035 http://dx.doi.org/10.1186/s12934-020-01449-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jia, Shuo Huang, Xinning Li, Hua Zheng, Dianzhong Wang, Li Qiao, Xinyuan Jiang, Yanping Cui, Wen Tang, Lijie Li, Yijing Xu, Yigang Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant |
title | Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant |
title_full | Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant |
title_fullStr | Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant |
title_full_unstemmed | Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant |
title_short | Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant |
title_sort | immunogenicity evaluation of recombinant lactobacillus casei w56 expressing bovine viral diarrhea virus e2 protein in conjunction with cholera toxin b subunit as an adjuvant |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527787/ https://www.ncbi.nlm.nih.gov/pubmed/33004035 http://dx.doi.org/10.1186/s12934-020-01449-3 |
work_keys_str_mv | AT jiashuo immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT huangxinning immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT lihua immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT zhengdianzhong immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT wangli immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT qiaoxinyuan immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT jiangyanping immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT cuiwen immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT tanglijie immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT liyijing immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant AT xuyigang immunogenicityevaluationofrecombinantlactobacilluscaseiw56expressingbovineviraldiarrheaviruse2proteininconjunctionwithcholeratoxinbsubunitasanadjuvant |